AMPHOTERICIN-B OVERDOSE IN PEDIATRIC-PATIENTS WITH ASSOCIATED CARDIAC-ARREST

被引:23
作者
CLEARY, JD
HAYMAN, J
SHERWOOD, J
LASALA, GP
PIAZZAHEPP, T
机构
[1] CHILDRENS CLIN, JACKSON, MS USA
[2] PARKLAND MEM HOSP & AFFILIATED INST, PHARM SERV, DALLAS, TX 75235 USA
[3] UNIV MISSISSIPPI, MED CTR, SCH MED, JACKSON, MS 39216 USA
[4] US FDA, DIV EPIDEMIOL & SURVEILLANCE, ROCKVILLE, MD 20857 USA
关键词
D O I
10.1177/106002809302700607
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population. Treatment is also presented. SETTING: Hospital. PATIENTS: Two infants and three children inpatients receiving amphotericin B. INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B. Cardiac arrest occurred in all patients, and four patients died. A detailed description of the cardiac event is provided for one patient who was on a cardiac monitor during the adverse reaction. Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor). Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias. CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants. The presentation in humans appears similar to that in dogs where cardiac arrhythmias occurred at doses of 5-15 mg/kg. Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses. Animal studies are necessary to evaluate this observation and potential disadvantages of hydrocortisone usage.
引用
收藏
页码:715 / 719
页数:5
相关论文
共 26 条
[1]  
[Anonymous], 1985, MANUAL CLIN MICROBIO
[2]   PHARMACOKINETICS, OUTCOME OF TREATMENT, AND TOXIC EFFECTS OF AMPHOTERICIN-B AND 5-FLUOROCYTOSINE IN NEONATES [J].
BALEY, JE ;
MEYERS, C ;
KLIEGMAN, RM ;
JACOBS, MR ;
BLUMER, JL .
JOURNAL OF PEDIATRICS, 1990, 116 (05) :791-797
[3]  
BOWLER WA, 1990, 1990 INT C ANT AG CH, P567
[4]  
BRENT J, 1990, VET HUM TOXICOL, V32, P124
[5]  
BUTLER WT, 1964, P SOC EXP BIOL MED, V116, P857, DOI 10.3181/00379727-116-29391
[6]  
CAPUOZZO E, 1990, BIOCHEM INT, V20, P1135
[7]   DISTRIBUTION AND ACTIVITY OF AMPHOTERICIN-B IN HUMANS [J].
CHRISTIANSEN, KJ ;
BERNARD, EM ;
GOLD, JWM ;
ARMSTRONG, D .
JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (05) :1037-1043
[8]  
CHUNG DK, 1971, AM REV RESPIR DIS, V103, P831
[9]   PHARMACOLOGICAL MODULATION OF INTERLEUKIN-1 EXPRESSION BY AMPHOTERICIN B-STIMULATED HUMAN MONONUCLEAR-CELLS [J].
CLEARY, JD ;
CHAPMAN, SW ;
NOLAN, RL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) :977-981
[10]   RISK-FACTORS OF VENTRICULAR-FIBRILLATION DURING RAPID AMPHOTERICIN-B INFUSION [J].
CRAVEN, PC ;
GREMILLION, DH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (05) :868-871